| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Robert H. Purcell | Q2157414 |
| Mahtab Moayeri | Q62580112 | ||
| P2093 | author name string | Zhaochun Chen | |
| P2860 | cites work | Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly | Q81321290 |
| Postexposure prophylaxis against experimental inhalation anthrax | Q64051299 | ||
| A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo | Q69243931 | ||
| Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies | Q71679438 | ||
| Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies | Q72310318 | ||
| Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques | Q74818408 | ||
| A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor | Q79890058 | ||
| Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate | Q44810979 | ||
| Genetic immunization against anthrax | Q44833567 | ||
| Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule | Q44840200 | ||
| Selection of Bacillus anthracis isolates resistant to antibiotics | Q44942836 | ||
| Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. | Q45736635 | ||
| Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins | Q45762836 | ||
| A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers | Q46529537 | ||
| Quantitative analysis of the effect of cell type and cellular differentiation on protective antigen binding to human target cells. | Q51806044 | ||
| Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen | Q24320977 | ||
| Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor | Q24532224 | ||
| Contribution of individual toxin components to virulence of Bacillus anthracis | Q24652917 | ||
| Bacillus anthracis | Q24672893 | ||
| Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax | Q24682011 | ||
| Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings | Q24718884 | ||
| Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed | Q24806902 | ||
| The Sverdlovsk anthrax outbreak of 1979 | Q28241641 | ||
| Raxibacumab for the treatment of inhalational anthrax | Q28251284 | ||
| Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor | Q28269030 | ||
| In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity | Q28383065 | ||
| Conference report on public health and clinical guidelines for anthrax | Q28386084 | ||
| Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection | Q28389813 | ||
| Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001 | Q28390531 | ||
| A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge | Q28398021 | ||
| Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells | Q28609196 | ||
| Anthrax as a biological weapon, 2002: updated recommendations for management | Q29615587 | ||
| Passive transfer of protection against Bacillus anthracis infection in a murine model | Q30696618 | ||
| Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine | Q33195848 | ||
| Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model | Q33203095 | ||
| Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy | Q33227409 | ||
| Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen | Q33232901 | ||
| Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule | Q33261310 | ||
| Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax | Q33739694 | ||
| Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis | Q33756961 | ||
| Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax | Q33877222 | ||
| Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence | Q33962064 | ||
| Search for correlates of protective immunity conferred by anthrax vaccine | Q34007168 | ||
| Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein | Q34008307 | ||
| An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin | Q34033505 | ||
| Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody | Q34038244 | ||
| Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex | Q34069693 | ||
| Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization | Q34117219 | ||
| Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice | Q34167973 | ||
| Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro | Q34289924 | ||
| Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax | Q34334451 | ||
| Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule | Q34490786 | ||
| Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice | Q34545842 | ||
| Receptors of anthrax toxin and cell entry. | Q34659076 | ||
| Passive antibody administration (immediate immunity) as a specific defense against biological weapons | Q34762095 | ||
| Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity | Q35073821 | ||
| Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine | Q35171265 | ||
| Protective immunity induced by Bacillus anthracis toxin-deficient strains. | Q35400677 | ||
| Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs | Q35560377 | ||
| The roles of anthrax toxin in pathogenesis | Q35702957 | ||
| A dually active anthrax vaccine that confers protection against both bacilli and toxins | Q35978682 | ||
| Human antibodies from transgenic animals | Q36252986 | ||
| Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice | Q36469606 | ||
| Poly-gamma-glutamate in bacteria | Q36475462 | ||
| Characterization of the interaction between anthrax toxin and its cellular receptors | Q36761999 | ||
| Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin | Q36982457 | ||
| Immunization studies with attenuated strains of Bacillus anthracis | Q37029061 | ||
| Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding | Q37304034 | ||
| Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody | Q37333457 | ||
| mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia | Q37416012 | ||
| Cellular and systemic effects of anthrax lethal toxin and edema toxin | Q37441837 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen | Q37521734 | ||
| In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin | Q39776135 | ||
| Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor | Q40046283 | ||
| Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies | Q40204434 | ||
| Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody | Q40644450 | ||
| In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. | Q40689685 | ||
| The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins | Q40738802 | ||
| Development of novel vaccines against anthrax in man. | Q41039399 | ||
| Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model | Q41869569 | ||
| Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin | Q43581522 | ||
| The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. | Q43629044 | ||
| In vitro correlate of immunity in a rabbit model of inhalational anthrax | Q43727746 | ||
| Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity | Q44013452 | ||
| Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis | Q44735551 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| ANTRAX | Q129104 | ||
| globulins | Q321710 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| immunotherapy | Q1427096 | ||
| bacterial antigens | Q65983976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1004-19 | |
| P577 | publication date | 2011-08-01 | |
| P1433 | published in | Toxins | Q15724569 |
| P1476 | title | Monoclonal antibody therapies against anthrax | |
| P478 | volume | 3 |
| Q40570352 | A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection |
| Q35808793 | A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax |
| Q35173029 | A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model |
| Q36665638 | Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice |
| Q28075453 | Alternative pre-approved and novel therapies for the treatment of anthrax |
| Q26852034 | Anthrax lethal and edema toxins in anthrax pathogenesis |
| Q26781366 | Anthrax prophylaxis: recent advances and future directions |
| Q38760476 | Anti-virulence Strategies to Target Bacterial Infections |
| Q30201937 | Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule". |
| Q27000357 | Bacillus anthracis edema factor substrate specificity: evidence for new modes of action |
| Q53718587 | Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era. |
| Q36991788 | Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections |
| Q30389824 | Biochip for the Detection of Bacillus anthracis Lethal Factor and Therapeutic Agents against Anthrax Toxins. |
| Q36970210 | Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay |
| Q59797645 | Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies |
| Q36911369 | Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays |
| Q37065380 | Controlled release of an anthrax toxin-neutralizing antibody from hydrolytically degradable polyethylene glycol hydrogels |
| Q35018313 | Designing inhibitors of anthrax toxin |
| Q49444286 | Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen |
| Q35749538 | Development of an in vitro potency assay for anti-anthrax lethal toxin neutralizing antibodies |
| Q39197564 | Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance |
| Q28389738 | Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax |
| Q89132174 | Engineering therapeutic antibodies to combat infectious diseases |
| Q90009925 | Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model |
| Q35548062 | Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine |
| Q36007463 | Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization |
| Q34290957 | Identification of peptide sequences as a measure of Anthrax vaccine stability during storage |
| Q39215653 | Immunotherapy for infectious diseases in haematological immunocompromise |
| Q90225928 | Inhibition of Pore-Forming Proteins |
| Q36482706 | MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen |
| Q34761514 | Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor |
| Q26825548 | Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases |
| Q90176689 | Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria |
| Q38809942 | Obiltoxaximab: First Global Approval |
| Q26827489 | Obstructing toxin pathways by targeted pore blockage |
| Q28392599 | Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax |
| Q90212156 | Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections |
| Q39331773 | Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy |
| Q34486875 | Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis |
| Q38210540 | Raxibacumab: potential role in the treatment of inhalational anthrax |
| Q37124221 | Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection |
| Q47106926 | The Potential Pathogenic Contributions of Endothelial Barrier and Arterial Contractile Dysfunction to Shock Due to B. anthracis Lethal and Edema Toxins |
| Q37453046 | Toxin-independent virulence of Bacillus anthracis in rabbits |
Search more.